These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18549939)

  • 21. Cholesterol and coronary events. The current thinking.
    Jones PH
    Postgrad Med; 2003 Apr; 113(4 Suppl):5-14. PubMed ID: 19667618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.
    Sachdeva A; Cannon CP; Deedwania PC; Labresh KA; Smith SC; Dai D; Hernandez A; Fonarow GC
    Am Heart J; 2009 Jan; 157(1):111-117.e2. PubMed ID: 19081406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
    Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
    Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy.
    Fitzgerald TN; Popp C; Dardik A; Federman DG
    Vasc Med; 2009 Feb; 14(1):21-7. PubMed ID: 19144776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of patients discharged from pharmacy-managed cardiovascular disease management.
    Olson KL; Delate T; Rasmussen J; Humphries TL; Merenich JA;
    Am J Manag Care; 2009 Aug; 15(8):497-503. PubMed ID: 19670953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuation of statin treatment and all-cause mortality: a population-based cohort study.
    Shalev V; Chodick G; Silber H; Kokia E; Jan J; Heymann AD
    Arch Intern Med; 2009 Feb; 169(3):260-8. PubMed ID: 19204217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of statin medications on prostate-specific antigen levels.
    Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
    Kostapanos MS; Milionis HJ; Lagos KG; Rizos CB; Tselepis AD; Elisaf MS
    Eur J Pharmacol; 2008 Aug; 590(1-3):327-32. PubMed ID: 18585701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study).
    Wiviott SD; Mohanavelu S; Raichlen JS; Cain VA; Nissen SE; Libby P
    Am J Cardiol; 2009 Jul; 104(1):29-35. PubMed ID: 19576317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG).
    Javed U; Deedwania PC; Bhatt DL; Cannon CP; Dai D; Hernandez AF; Peterson ED; Fonarow GC
    Am Heart J; 2010 Dec; 160(6):1130-6, 1136.e1-3. PubMed ID: 21146668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternate-day dosing of statins for secondary prevention of coronary artery disease/The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Celik M; Celik T
    Anadolu Kardiyol Derg; 2009 Jun; 9(3):253; author reply 253-4. PubMed ID: 19520663
    [No Abstract]   [Full Text] [Related]  

  • 32. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary prevention for acute coronary syndrome in rural South Australia: are drugs best? What about the rest?
    Wachtel TM; Kucia AM; Greenhill JA
    Rural Remote Health; 2008; 8(4):967. PubMed ID: 18855517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Influence of use of the direct LDL-cholesterol (LDL-C) assay on diagnosis and treatment for patients with hyperlipidemia--analysis using the hospital information system].
    Goto S; Ohsawa I; Watanabe T; Sakai K; Shibata K; Kato T; Oshida Y; Sato Y
    Rinsho Byori; 2005 Jun; 53(6):509-13. PubMed ID: 16026077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The patient at risk: who should we be treating?
    Leitersdorf E
    Br J Clin Pract Suppl; 1994 Dec; (77):24-7. PubMed ID: 19496269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of genetic variants associated with response to statin therapy.
    Mega JL; Morrow DA; Brown A; Cannon CP; Sabatine MS
    Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1310-5. PubMed ID: 19667110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.